# Cardiovascular Agents: Angina, Hypertension & Heart Failure

**LENGTH OF AUTHORIZATIONS:**  365 Days

**PRIOR AUTHORIZATION CRITERIA:**

Is there any reason the patient cannot be changed to a medication not requiring prior approval?

Acceptable reasons include:

- Allergy to all medications not requiring prior approval

- Contraindication to or drug-to-drug interaction with medications not requiring prior approval.

- History of unacceptable/toxic side effects to medications not requiring prior approval

**CORLANOR** **CRITERIA:**

Ivabradine (Corlanor) may be approved if all of the following are met:

1. Diagnosis of stable, symptomatic heart failure, and
2. Left ventricular ejection fraction less than or equal to 35%, and
3. Resting heart rate 70 bpm or higher, and
4. Patient in sinus rhythm, and
5. Heart failure symptoms persisting with maximally tolerated doses of beta blockers, or patient has a contraindication to beta blocker therapy.

**ENTRESTO CRITERIA:**

Valsartan/sacubitril (Entresto) may be approved if all the following are met:

1. Diagnosis of chronic heart failure (NYHA Class II-IV), and
2. Reduced left ventricular ejection fraction

**ALISKIREN AND TEKTURNA HCT CRITERIA:**

Aliskiren and Tekturna HCT may be approved if all the following are met:

1. A 30-day trial of any one preferred anti-hypertensive agent

**VERQUVO CRITERIA:**

1. Patient must meet all the following criteria:

    - Diagnosis of symptomatic chronic heart failure (NYHA Class II-IV), and
    - Left ventricular ejection fraction less than 45%, and
    - Patient has been hospitalized for the treatment of heart failure within the previous 180 days or needs treatment with an outpatient intravenous diuretic within the previous 90 days, and
    - Patient must be treated with an agent from ALL the following medication classes unless contradicted:

        - Angiotensin-converting enzyme inhibitor, angiotensin II receptor blocker, or an angiotensin receptor neprilysin inhibitor
        - Beta-blocker
        - Aldosterone antagonist and/or SGLT2 inhibitor as appropriate for renal function

**KERENDIA CRITERIA:**

1. Patient must meet all the following criteria:

    - A diagnosis of Chronic Kidney Disease due to Type 2 Diabetes
    - Be on maximum tolerated dose of an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker
    - Allergy, intolerance, or inadequate response to an SGLT2 Inhibitor

**ADDITIONAL APPROVAL CRITERIA:**

1. The requested medication may be approved if both of the following are true:

    - If there has been a therapeutic failure to no less than a 30-day trial of at least two medications within the same class not requiring prior approval

    - The requested medicationâ€™s corresponding generic (if covered by the state) has been attempted and failed or is contraindicated

2. If there is a specific indication for a medication requiring prior approval, for which medications not requiring prior approval are not indicated, then may approve the requested medication. This medication should be reviewed for need at each request for reauthorization.
3. Nimodipine only approvable for 21 days after subarachnoid hemorrhage

AR - Hemangeol oral solution: a PA is required for patients over 2 years old
